Jay Kim

Company: K2B Therapeutics

Job title: Chief Executive Officer

Seminars:

Novel Protein Conjugate for Delivering siRNAs to Tumor Cells 4:00 pm

• Discussing the development of the 4th generation technology for targeted delivery of siRNA to extrahepatic tissues • Describing functional and development advantages of protein-siRNA conjugate (PRC) technology • What are the most exciting therapeutic targets that take advantage of targeted siRNA delivery?Read more

day: Conference Day One